Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 30247 | 1.34 |
09:38 ET | 400 | 1.3405 |
09:39 ET | 100 | 1.34 |
09:41 ET | 1597 | 1.335 |
09:43 ET | 900 | 1.33 |
09:45 ET | 2800 | 1.32 |
09:48 ET | 600 | 1.32 |
09:50 ET | 600 | 1.32 |
09:52 ET | 6000 | 1.31 |
09:54 ET | 600 | 1.31 |
09:56 ET | 5389 | 1.31 |
09:57 ET | 4687 | 1.31 |
09:59 ET | 1694 | 1.3 |
10:01 ET | 955 | 1.3 |
10:03 ET | 500 | 1.3 |
10:06 ET | 1251 | 1.3082 |
10:08 ET | 2600 | 1.3 |
10:10 ET | 500 | 1.3 |
10:12 ET | 400 | 1.3 |
10:14 ET | 1031 | 1.3 |
10:15 ET | 500 | 1.3 |
10:17 ET | 433 | 1.31 |
10:19 ET | 833 | 1.305 |
10:21 ET | 526 | 1.3 |
10:24 ET | 588 | 1.3 |
10:26 ET | 7834 | 1.32 |
10:28 ET | 8050 | 1.31 |
10:30 ET | 10413 | 1.31 |
10:32 ET | 4999 | 1.315 |
10:33 ET | 4119 | 1.31 |
10:35 ET | 2693 | 1.31 |
10:37 ET | 3500 | 1.31 |
10:39 ET | 6320 | 1.3 |
10:42 ET | 22205 | 1.3 |
10:44 ET | 4623 | 1.3 |
10:46 ET | 2420 | 1.3 |
10:48 ET | 9181 | 1.29 |
10:50 ET | 8676 | 1.29 |
10:51 ET | 4658 | 1.29 |
10:53 ET | 5376 | 1.29 |
10:55 ET | 15073 | 1.29 |
10:57 ET | 5383 | 1.29 |
11:00 ET | 59343 | 1.29 |
11:02 ET | 4000 | 1.29 |
11:04 ET | 5690 | 1.285 |
11:06 ET | 3100 | 1.28 |
11:08 ET | 3872 | 1.29 |
11:09 ET | 23544 | 1.2915 |
11:11 ET | 7063 | 1.29 |
11:13 ET | 15585 | 1.29 |
11:15 ET | 20412 | 1.29 |
11:18 ET | 7953 | 1.295 |
11:20 ET | 3425 | 1.285 |
11:22 ET | 200 | 1.28 |
11:24 ET | 1860 | 1.28 |
11:26 ET | 6846 | 1.284 |
11:27 ET | 1575 | 1.2805 |
11:29 ET | 700 | 1.28 |
11:31 ET | 2220 | 1.28 |
11:33 ET | 1007 | 1.29 |
11:36 ET | 31498 | 1.27 |
11:38 ET | 3311 | 1.28 |
11:40 ET | 1800 | 1.275 |
11:42 ET | 1600 | 1.275 |
11:44 ET | 1758 | 1.28 |
11:45 ET | 4700 | 1.27 |
11:47 ET | 600 | 1.28 |
11:49 ET | 1550 | 1.27 |
11:51 ET | 1430 | 1.28 |
11:54 ET | 3029 | 1.27 |
11:56 ET | 800 | 1.275 |
11:58 ET | 1222 | 1.275 |
12:00 ET | 5944 | 1.27 |
12:02 ET | 700 | 1.27 |
12:03 ET | 3700 | 1.27 |
12:05 ET | 700 | 1.275 |
12:07 ET | 12633 | 1.27 |
12:09 ET | 1898 | 1.275 |
12:12 ET | 500 | 1.275 |
12:14 ET | 400 | 1.27 |
12:16 ET | 2173 | 1.28 |
12:18 ET | 700 | 1.27 |
12:20 ET | 2969 | 1.27 |
12:21 ET | 100 | 1.27 |
12:23 ET | 700 | 1.27 |
12:25 ET | 2000 | 1.27 |
12:27 ET | 6881 | 1.27 |
12:30 ET | 49848 | 1.26 |
12:32 ET | 11900 | 1.26 |
12:34 ET | 7243 | 1.265 |
12:36 ET | 2686 | 1.2698 |
12:38 ET | 9278 | 1.26 |
12:39 ET | 127419 | 1.25 |
12:41 ET | 8126 | 1.25 |
12:43 ET | 6200 | 1.24 |
12:45 ET | 2899 | 1.249 |
12:48 ET | 17392 | 1.255 |
12:50 ET | 9670 | 1.25 |
12:52 ET | 5452 | 1.25 |
12:54 ET | 9015 | 1.25 |
12:56 ET | 62820 | 1.25 |
12:57 ET | 6840 | 1.25 |
12:59 ET | 1271 | 1.256 |
01:06 ET | 410 | 1.25 |
01:08 ET | 11100 | 1.25 |
01:10 ET | 500 | 1.255 |
01:12 ET | 400 | 1.25 |
01:14 ET | 7125 | 1.255 |
01:15 ET | 3253 | 1.25 |
01:17 ET | 900 | 1.25 |
01:19 ET | 500 | 1.255 |
01:21 ET | 5969 | 1.25 |
01:24 ET | 1723 | 1.26 |
01:26 ET | 1700 | 1.255 |
01:28 ET | 2400 | 1.26 |
01:30 ET | 1300 | 1.26 |
01:32 ET | 1574 | 1.26 |
01:33 ET | 1200 | 1.255 |
01:35 ET | 600 | 1.255 |
01:37 ET | 1220 | 1.255 |
01:39 ET | 2150 | 1.255 |
01:42 ET | 10286 | 1.265 |
01:44 ET | 1500 | 1.27 |
01:46 ET | 11628 | 1.2701 |
01:48 ET | 2824 | 1.275 |
01:50 ET | 3800 | 1.2793 |
01:51 ET | 100 | 1.28 |
01:55 ET | 600 | 1.28 |
01:57 ET | 65282 | 1.26 |
02:00 ET | 5315 | 1.26 |
02:02 ET | 8400 | 1.26 |
02:04 ET | 300 | 1.26 |
02:06 ET | 400 | 1.26 |
02:08 ET | 300 | 1.26 |
02:09 ET | 200 | 1.26 |
02:11 ET | 600 | 1.26 |
02:13 ET | 400 | 1.26 |
02:15 ET | 400 | 1.265 |
02:18 ET | 600 | 1.26 |
02:20 ET | 2400 | 1.265 |
02:22 ET | 1200 | 1.26 |
02:24 ET | 15813 | 1.26 |
02:26 ET | 4927 | 1.26 |
02:27 ET | 7100 | 1.255 |
02:29 ET | 87807 | 1.25 |
02:31 ET | 12465 | 1.255 |
02:33 ET | 6913 | 1.255 |
02:36 ET | 1100 | 1.255 |
02:38 ET | 4845 | 1.25 |
02:40 ET | 14800 | 1.255 |
02:42 ET | 8982 | 1.245 |
02:44 ET | 9354 | 1.25 |
02:45 ET | 3400 | 1.24 |
02:47 ET | 2879 | 1.25 |
02:49 ET | 2000 | 1.24 |
02:51 ET | 2200 | 1.24 |
02:54 ET | 9291 | 1.24 |
02:56 ET | 8368 | 1.25 |
02:58 ET | 4318 | 1.25 |
03:00 ET | 17056 | 1.24 |
03:02 ET | 2800 | 1.245 |
03:03 ET | 2631 | 1.24 |
03:05 ET | 2200 | 1.24 |
03:07 ET | 81889 | 1.23 |
03:09 ET | 8020 | 1.23 |
03:12 ET | 47315 | 1.235 |
03:14 ET | 22500 | 1.23 |
03:16 ET | 15877 | 1.235 |
03:18 ET | 8270 | 1.235 |
03:20 ET | 347565 | 1.235 |
03:21 ET | 10300 | 1.235 |
03:23 ET | 59315 | 1.23 |
03:25 ET | 2700 | 1.235 |
03:27 ET | 3000 | 1.23 |
03:30 ET | 1600 | 1.235 |
03:32 ET | 52712 | 1.22 |
03:34 ET | 55791 | 1.22 |
03:36 ET | 7796 | 1.225 |
03:38 ET | 6300 | 1.225 |
03:39 ET | 5528 | 1.225 |
03:41 ET | 81857 | 1.215 |
03:43 ET | 5085 | 1.21 |
03:45 ET | 10971 | 1.21 |
03:48 ET | 5800 | 1.21 |
03:50 ET | 3600 | 1.215 |
03:52 ET | 6224 | 1.22 |
03:54 ET | 16370 | 1.2199 |
03:56 ET | 102345 | 1.21 |
03:57 ET | 77720 | 1.21 |
03:59 ET | 108202 | 1.21 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 103.6M | 6.1x | --- |
Spero Therapeutics Inc | 71.8M | 3.2x | --- |
2Seventy Bio Inc | 198.4M | -0.9x | --- |
G1 Therapeutics Inc | 116.1M | -3.6x | --- |
Rigel Pharmaceuticals Inc | 167.7M | -7.4x | --- |
Seres Therapeutics Inc | 114.9M | -1.2x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $103.6M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.07 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 6.1x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | 5.6x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.